Nektar Therapeutics (NKTR)
USD 0.56
(-6.09%)
USD 0.56
(-6.09%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 267.04 Million USD | -22.36% |
| 2022 | 343.96 Million USD | -21.41% |
| 2021 | 437.68 Million USD | -5.16% |
| 2020 | 461.47 Million USD | -19.32% |
| 2019 | 571.96 Million USD | 32.22% |
| 2018 | 432.59 Million USD | 2.75% |
| 2017 | 421.03 Million USD | -12.42% |
| 2016 | 480.74 Million USD | -3.0% |
| 2015 | 495.63 Million USD | 22.29% |
| 2014 | 405.28 Million USD | -22.72% |
| 2013 | 524.43 Million USD | 16.34% |
| 2012 | 450.77 Million USD | 10.28% |
| 2011 | 408.73 Million USD | -5.07% |
| 2010 | 430.56 Million USD | -9.0% |
| 2009 | 473.15 Million USD | 27.75% |
| 2008 | 370.38 Million USD | -27.47% |
| 2007 | 510.66 Million USD | -5.63% |
| 2006 | 541.11 Million USD | 1.76% |
| 2005 | 531.74 Million USD | 91.56% |
| 2004 | 277.57 Million USD | -38.67% |
| 2003 | 452.59 Million USD | 13.19% |
| 2002 | 399.86 Million USD | 0.74% |
| 2001 | 396.92 Million USD | 12.87% |
| 2000 | 351.65 Million USD | 150.87% |
| 1999 | 140.17 Million USD | 653.03% |
| 1998 | 18.61 Million USD | -17.88% |
| 1997 | 22.66 Million USD | 254.2% |
| 1996 | 6.4 Million USD | 113.33% |
| 1995 | 3 Million USD | 66.67% |
| 1994 | 1.8 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 269.3 Million USD | 0.85% |
| 2024 Q2 | 263.64 Million USD | -2.1% |
| 2023 Q2 | 297.32 Million USD | -7.34% |
| 2023 Q1 | 320.87 Million USD | -6.71% |
| 2023 FY | 267.04 Million USD | -22.36% |
| 2023 Q3 | 282.87 Million USD | -4.86% |
| 2023 Q4 | 267.04 Million USD | -5.6% |
| 2022 Q2 | 403.25 Million USD | -3.12% |
| 2022 Q3 | 368.78 Million USD | -8.55% |
| 2022 Q1 | 416.22 Million USD | -4.9% |
| 2022 FY | 343.96 Million USD | -21.41% |
| 2022 Q4 | 343.96 Million USD | -6.73% |
| 2021 Q4 | 437.68 Million USD | -7.99% |
| 2021 FY | 437.68 Million USD | -5.16% |
| 2021 Q1 | 462.05 Million USD | 0.13% |
| 2021 Q2 | 466.37 Million USD | 0.94% |
| 2021 Q3 | 475.7 Million USD | 2.0% |
| 2020 Q3 | 337.68 Million USD | -0.28% |
| 2020 Q2 | 338.63 Million USD | -42.75% |
| 2020 FY | 461.47 Million USD | -19.32% |
| 2020 Q4 | 461.47 Million USD | 36.66% |
| 2020 Q1 | 591.5 Million USD | 3.42% |
| 2019 FY | 571.96 Million USD | 32.22% |
| 2019 Q3 | 599.58 Million USD | 10.52% |
| 2019 Q4 | 571.96 Million USD | -4.61% |
| 2019 Q1 | 532.97 Million USD | 23.2% |
| 2019 Q2 | 542.49 Million USD | 1.79% |
| 2018 Q2 | 452.67 Million USD | 3.23% |
| 2018 Q4 | 432.59 Million USD | -5.75% |
| 2018 FY | 432.59 Million USD | 2.75% |
| 2018 Q1 | 438.5 Million USD | 4.15% |
| 2018 Q3 | 458.97 Million USD | 1.39% |
| 2017 FY | 421.03 Million USD | -12.42% |
| 2017 Q4 | 421.03 Million USD | -15.44% |
| 2017 Q3 | 497.89 Million USD | 5.38% |
| 2017 Q2 | 472.47 Million USD | -2.33% |
| 2017 Q1 | 483.73 Million USD | 0.62% |
| 2016 Q3 | 492.94 Million USD | -1.87% |
| 2016 Q1 | 492.15 Million USD | -0.7% |
| 2016 Q2 | 502.35 Million USD | 2.07% |
| 2016 FY | 480.74 Million USD | -3.0% |
| 2016 Q4 | 480.74 Million USD | -2.48% |
| 2015 Q4 | 495.63 Million USD | 20.83% |
| 2015 Q1 | 421.9 Million USD | 4.1% |
| 2015 Q3 | 410.19 Million USD | -2.7% |
| 2015 FY | 495.63 Million USD | 22.29% |
| 2015 Q2 | 421.56 Million USD | -0.08% |
| 2014 FY | 405.28 Million USD | -22.72% |
| 2014 Q2 | 513.49 Million USD | 3.36% |
| 2014 Q3 | 429.68 Million USD | -16.32% |
| 2014 Q1 | 496.82 Million USD | -5.26% |
| 2014 Q4 | 405.28 Million USD | -5.68% |
| 2013 Q1 | 450.52 Million USD | -0.06% |
| 2013 Q3 | 433.28 Million USD | -4.43% |
| 2013 FY | 524.43 Million USD | 16.34% |
| 2013 Q4 | 524.43 Million USD | 21.04% |
| 2013 Q2 | 453.35 Million USD | 0.63% |
| 2012 Q3 | 446.12 Million USD | -16.79% |
| 2012 Q1 | 532.3 Million USD | 30.23% |
| 2012 FY | 450.77 Million USD | 10.28% |
| 2012 Q4 | 450.77 Million USD | 1.04% |
| 2012 Q2 | 536.15 Million USD | 0.72% |
| 2011 Q3 | 417.29 Million USD | -0.54% |
| 2011 Q2 | 419.57 Million USD | -0.87% |
| 2011 Q1 | 423.24 Million USD | -1.7% |
| 2011 FY | 408.73 Million USD | -5.07% |
| 2011 Q4 | 408.73 Million USD | -2.05% |
| 2010 Q1 | 443.75 Million USD | -6.21% |
| 2010 FY | 430.56 Million USD | -9.0% |
| 2010 Q4 | 430.56 Million USD | 8.86% |
| 2010 Q3 | 395.52 Million USD | -6.07% |
| 2010 Q2 | 421.1 Million USD | -5.1% |
| 2009 Q2 | 342.4 Million USD | -1.23% |
| 2009 FY | 473.15 Million USD | 27.75% |
| 2009 Q3 | 346.55 Million USD | 1.21% |
| 2009 Q1 | 346.66 Million USD | -6.4% |
| 2009 Q4 | 473.15 Million USD | 36.53% |
| 2008 Q4 | 370.38 Million USD | -19.43% |
| 2008 Q1 | 468.07 Million USD | -8.34% |
| 2008 Q2 | 465.79 Million USD | -0.49% |
| 2008 Q3 | 459.72 Million USD | -1.3% |
| 2008 FY | 370.38 Million USD | -27.47% |
| 2007 Q2 | 514.78 Million USD | 2.32% |
| 2007 Q4 | 510.66 Million USD | -10.0% |
| 2007 Q3 | 567.38 Million USD | 10.22% |
| 2007 FY | 510.66 Million USD | -5.63% |
| 2007 Q1 | 503.11 Million USD | -7.02% |
| 2006 Q1 | 534.73 Million USD | 0.56% |
| 2006 Q3 | 538.33 Million USD | -4.19% |
| 2006 Q4 | 541.11 Million USD | 0.52% |
| 2006 FY | 541.11 Million USD | 1.76% |
| 2006 Q2 | 561.88 Million USD | 5.08% |
| 2005 Q3 | 512.8 Million USD | 88.03% |
| 2005 FY | 531.74 Million USD | 91.56% |
| 2005 Q1 | 270.18 Million USD | -2.66% |
| 2005 Q2 | 272.73 Million USD | 0.94% |
| 2005 Q4 | 531.74 Million USD | 3.69% |
| 2004 FY | 277.57 Million USD | -38.67% |
| 2004 Q4 | 277.57 Million USD | 6.37% |
| 2004 Q3 | 260.96 Million USD | -0.98% |
| 2004 Q2 | 263.55 Million USD | -4.58% |
| 2004 Q1 | 276.19 Million USD | -38.98% |
| 2003 Q2 | 459.82 Million USD | 22.1% |
| 2003 Q1 | 376.6 Million USD | -5.82% |
| 2003 Q3 | 474.33 Million USD | 3.15% |
| 2003 FY | 452.59 Million USD | 13.19% |
| 2003 Q4 | 452.59 Million USD | -4.58% |
| 2002 Q3 | 389.88 Million USD | -1.25% |
| 2002 Q1 | 396.53 Million USD | -0.1% |
| 2002 Q4 | 399.86 Million USD | 2.56% |
| 2002 FY | 399.86 Million USD | 0.74% |
| 2002 Q2 | 394.83 Million USD | -0.43% |
| 2001 Q1 | 366.61 Million USD | 4.25% |
| 2001 Q2 | 393.86 Million USD | 7.43% |
| 2001 Q3 | 383.1 Million USD | -2.73% |
| 2001 Q4 | 396.92 Million USD | 3.61% |
| 2001 FY | 396.92 Million USD | 12.87% |
| 2000 Q4 | 351.65 Million USD | 32.12% |
| 2000 Q3 | 266.15 Million USD | -3.24% |
| 2000 Q1 | 278.41 Million USD | 98.62% |
| 2000 Q2 | 275.06 Million USD | -1.2% |
| 2000 FY | 351.65 Million USD | 150.87% |
| 1999 Q3 | 22.22 Million USD | 2.86% |
| 1999 Q4 | 140.17 Million USD | 530.75% |
| 1999 Q2 | 21.6 Million USD | 5.03% |
| 1999 Q1 | 20.57 Million USD | 10.51% |
| 1999 FY | 140.17 Million USD | 653.03% |
| 1998 FY | 18.61 Million USD | -17.88% |
| 1998 Q2 | 18.83 Million USD | -7.42% |
| 1998 Q1 | 20.34 Million USD | -10.26% |
| 1998 Q4 | 18.61 Million USD | 15.09% |
| 1998 Q3 | 16.17 Million USD | -14.12% |
| 1997 Q3 | 15 Million USD | 17.33% |
| 1997 FY | 22.66 Million USD | 254.2% |
| 1997 Q1 | 9.39 Million USD | 46.72% |
| 1997 Q2 | 12.78 Million USD | 36.18% |
| 1997 Q4 | 22.66 Million USD | 51.1% |
| 1996 Q1 | 2.9 Million USD | -3.33% |
| 1996 Q4 | 6.4 Million USD | 82.86% |
| 1996 Q3 | 3.5 Million USD | 6.06% |
| 1996 FY | 6.4 Million USD | 113.33% |
| 1996 Q2 | 3.3 Million USD | 13.79% |
| 1995 Q3 | 2.6 Million USD | -3.7% |
| 1995 FY | 3 Million USD | 66.67% |
| 1995 Q2 | 2.7 Million USD | -10.0% |
| 1995 Q1 | 3 Million USD | 66.67% |
| 1995 Q4 | 3 Million USD | 15.38% |
| 1994 FY | 1.8 Million USD | 0.0% |
| 1994 Q2 | 2.2 Million USD | 4.76% |
| 1994 Q3 | 2.6 Million USD | 18.18% |
| 1994 Q1 | 2.1 Million USD | 0.0% |
| 1994 Q4 | 1.8 Million USD | -30.77% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 20.469% |
| Alkermes plc | 933.53 Million USD | 71.394% |
| Agenus Inc. | 462.29 Million USD | 42.235% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 93.407% |
| Aptorum Group Limited | 5.25 Million USD | -4980.071% |
| Ardelyx, Inc. | 130.76 Million USD | -104.221% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 44.178% |
| Bicycle Therapeutics plc | 224.41 Million USD | -18.998% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -105.089% |
| ChromaDex Corporation | 26.5 Million USD | -907.417% |
| Chimerix, Inc. | 19.74 Million USD | -1252.474% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -659.147% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -267.999% |
| CRISPR Therapeutics AG | 346.76 Million USD | 22.99% |
| Precision BioSciences, Inc. | 140.92 Million USD | -89.502% |
| Dyadic International, Inc. | 2.34 Million USD | -11309.048% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -1542.046% |
| Fortress Biotech, Inc. | 165.93 Million USD | -60.93% |
| Lantern Pharma Inc. | 2.73 Million USD | -9647.336% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -273.595% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -7467.776% |
| Incyte Corporation | 1.59 Billion USD | 83.229% |
| IO Biotech, Inc. | 17.55 Million USD | -1421.11% |
| Jaguar Health, Inc. | 45.86 Million USD | -482.231% |
| Novavax, Inc. | 2.57 Billion USD | 89.618% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -640.601% |
| Opthea Limited | 264.6 Million USD | -0.924% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -104.309% |
| ContextLogic Inc. | 206 Million USD | -29.634% |
| MiMedx Group, Inc. | 96.33 Million USD | -177.22% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -456.091% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -7467.428% |
| NextCure, Inc. | 14.99 Million USD | -1680.663% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -6506.779% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -3899.491% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -471.356% |
| Vaxcyte, Inc. | 167.44 Million USD | -59.479% |
| PDS Biotechnology Corporation | 33.25 Million USD | -702.925% |
| Madrigal Pharmaceuticals, Inc. | 235.21 Million USD | -13.533% |
| Pharming Group N.V. | 244.07 Million USD | -9.412% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -2139.943% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -108.971% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -3941.694% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -3941.694% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -223.955% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -3919.961% |
| Acelyrin, Inc. | 86.35 Million USD | -209.249% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -20454.0% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -1757.195% |
| Summit Therapeutics Inc. | 125.25 Million USD | -113.198% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -2717.238% |
| Senti Biosciences, Inc. | 52.57 Million USD | -407.972% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -288.278% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -76.254% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -13552.658% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -19894.998% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -17.729% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -2750.923% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -17.411% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 45.998% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -2346.821% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -870.688% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -2106.135% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 45.12% |
| Immix Biopharma, Inc. | 3.72 Million USD | -7075.217% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -606.247% |
| MEI Pharma, Inc. | 8.35 Million USD | -3096.242% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -820.372% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 23.17% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -83.072% |
| Fortress Biotech, Inc. | 165.93 Million USD | -60.93% |
| Precigen, Inc. | 41.64 Million USD | -541.259% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -434.841% |
| AlloVir, Inc. | 45.01 Million USD | -493.238% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -104.889% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -93.792% |
| ImmuCell Corporation | 18.81 Million USD | -1319.323% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -846.099% |
| Onconetix, Inc. | 23.18 Million USD | -1052.009% |
| PureTech Health plc | 125.58 Million USD | -112.645% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -2883.754% |
| Elevation Oncology, Inc. | 34.28 Million USD | -678.969% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -10822.127% |
| Seer, Inc. | 39.36 Million USD | -578.384% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -331.876% |
| Innoviva, Inc. | 568.55 Million USD | 53.031% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -880.777% |
| ESSA Pharma Inc. | 3.49 Million USD | -7540.646% |
| GlycoMimetics, Inc. | 6.9 Million USD | -3769.069% |
| GT Biopharma, Inc. | 6.63 Million USD | -3926.021% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | -1.005% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 1.925% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -217.814% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -2632.208% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -882.907% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -8178.512% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -262.013% |
| Aptose Biosciences Inc. | 15.8 Million USD | -1589.234% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -2318.964% |
| Soligenix, Inc. | 7.27 Million USD | -3570.784% |
| Century Therapeutics, Inc. | 175.94 Million USD | -51.782% |
| Kura Oncology, Inc. | 51.66 Million USD | -416.91% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -120.186% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -6361.311% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -3937.675% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | -5.72% |
| Autolus Therapeutics plc | 263.9 Million USD | -1.189% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -2447.663% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -200.521% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -469.407% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 24.319% |
| GRI Bio, Inc. | 2.69 Million USD | -9801.594% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -32885.542% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -758.917% |
| IGM Biosciences, Inc. | 220.17 Million USD | -21.287% |
| INmune Bio, Inc. | 18.86 Million USD | -1315.788% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -4.12% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -902.357% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -9723.625% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -8040.986% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -356.84% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -177.713% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -0.873% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 67.553% |
| Verastem, Inc. | 71.18 Million USD | -275.144% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -443.041% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -592.224% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -445.749% |
| Histogen Inc. | 5.69 Million USD | -4587.485% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -5989.148% |
| Surrozen, Inc. | 8.14 Million USD | -3178.649% |
| Organovo Holdings, Inc. | 2.74 Million USD | -9617.831% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -84984.975% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -374.918% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -1517.284% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -422.564% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -32195.813% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -110.729% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -2369.541% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -76.982% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -10142.066% |
| Apollomics, Inc. | 14.15 Million USD | -1786.851% |
| Amarin Corporation plc | 279.58 Million USD | 4.486% |
| Mesoblast Limited | 188.79 Million USD | -41.445% |
| Turnstone Biologics Corp. | 14.14 Million USD | -1787.518% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -47.712% |
| Synaptogenix, Inc. | 5.52 Million USD | -4729.505% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -3916.937% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -56.986% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -3020.72% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -15095.577% |
| Exelixis, Inc. | 678.44 Million USD | 60.639% |
| Better Therapeutics, Inc. | 23.84 Million USD | -1020.065% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -62.787% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 55.059% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2400.383% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -16347.608% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -586.017% |
| Gritstone bio, Inc. | 125.91 Million USD | -112.078% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1719.61% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -5147.899% |
| Avid Bioservices, Inc. | 275.66 Million USD | 3.128% |
| Insmed Incorporated | 1.66 Billion USD | 83.93% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -3370.824% |
| MediWound Ltd. | 27.18 Million USD | -882.256% |
| OmniAb, Inc. | 87.4 Million USD | -205.545% |
| Alector, Inc. | 487.66 Million USD | 45.24% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 33.81% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -1349.368% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -595.922% |
| Zai Lab Limited | 240.17 Million USD | -11.187% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 57.616% |
| Aura Biosciences, Inc. | 29.22 Million USD | -813.696% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -180.873% |
| Immunic, Inc. | 25.36 Million USD | -952.688% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -285.704% |
| Veracyte, Inc. | 93.71 Million USD | -184.943% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -10105.555% |
| FibroGen, Inc. | 585.72 Million USD | 54.408% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1436.248% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -40790.494% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -4621.916% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 96.512% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -3157.453% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -217.829% |
| TG Therapeutics, Inc. | 169.08 Million USD | -57.936% |
| Galecto, Inc. | 5.89 Million USD | -4429.274% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -3123.636% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 89.801% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -826.535% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -2015.886% |
| XBiotech Inc. | 8.39 Million USD | -3080.255% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1719.61% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -402.155% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 26.455% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -893.327% |
| Theravance Biopharma, Inc. | 169 Million USD | -58.012% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 78.032% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 46.636% |
| Vaxxinity, Inc. | 30.94 Million USD | -762.998% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 72.54% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -4327.811% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 64.166% |
| NexImmune, Inc. | 5.08 Million USD | -5152.435% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -71803.693% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -8584.852% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 96.243% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -5081.305% |
| Scopus BioPharma Inc. | 7.45 Million USD | -3482.378% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -915.616% |
| Ainos, Inc. | 7.39 Million USD | -3511.549% |
| Pluri Inc. | 34.11 Million USD | -682.851% |
| Prothena Corporation plc | 135.01 Million USD | -97.787% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | -9.849% |
| Celularity Inc. | 102.92 Million USD | -159.447% |
| Rallybio Corporation | 9.43 Million USD | -2730.076% |
| Cue Biopharma, Inc. | 24.44 Million USD | -992.436% |
| MeiraGTx Holdings plc | 319.99 Million USD | 16.546% |
| Omeros Corporation | 403.25 Million USD | 33.777% |
| Humacyte, Inc. | 114.67 Million USD | -132.868% |
| Immunocore Holdings plc | 228.15 Million USD | -17.044% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -5377.867% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -247.988% |
| Blueprint Medicines Corporation | 918.64 Million USD | 70.93% |
| CalciMedica, Inc. | 4.02 Million USD | -6529.742% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -1430.174% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -73.246% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -211.181% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 3.869% |
| Pulmatrix, Inc. | 15.96 Million USD | -1572.906% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -1593.058% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -985.288% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -6.474% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -425.826% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 77.942% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -740.216% |
| Nutriband Inc. | 1.07 Million USD | -24651.256% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -2411.483% |
| Vor Biopharma Inc. | 59.1 Million USD | -351.824% |
| Roivant Sciences Ltd. | 773.95 Million USD | 65.496% |
| Evogene Ltd. | 17.99 Million USD | -1384.414% |
| ProKidney Corp. | 29.21 Million USD | -814.04% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -271.005% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -37779.779% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 85.862% |
| CorMedix Inc. | 11.91 Million USD | -2140.783% |
| BioLineRx Ltd. | 50.7 Million USD | -426.697% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -78.675% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -201.948% |
| Atai Life Sciences N.V. | 49.16 Million USD | -443.196% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -757.227% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -1386.728% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -114.261% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -4623.134% |
| MediciNova, Inc. | 3.89 Million USD | -6762.196% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -1360.944% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -17652.873% |
| GeoVax Labs, Inc. | 3.51 Million USD | -7486.791% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 32.778% |
| Biomea Fusion, Inc. | 30.69 Million USD | -770.14% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 90.188% |
| Mereo BioPharma Group plc | 15.96 Million USD | -1573.011% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -755.889% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -355.058% |
| Absci Corporation | 58.3 Million USD | -358.023% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1301.963% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -732.905% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -261.9% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -205.255% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -690.779% |
| Allakos Inc. | 74.79 Million USD | -257.047% |
| Imunon, Inc. | 8.53 Million USD | -3030.512% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -1086.818% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -132.594% |
| BioAtla, Inc. | 48.98 Million USD | -445.148% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2400.383% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -9509.428% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -104.47% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -1778.621% |
| XOMA Corporation | 145.58 Million USD | -83.436% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -693.245% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -288.38% |
| aTyr Pharma, Inc. | 31.59 Million USD | -745.163% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -331.953% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -493.897% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -451.725% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -9204.739% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -3173.418% |
| Akari Therapeutics, Plc | 4.58 Million USD | -5725.611% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1405.916% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 83.81% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -66015.551% |
| UroGen Pharma Ltd. | 243.52 Million USD | -9.659% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 16.831% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -9570.121% |
| Orgenesis Inc. | 35.53 Million USD | -651.501% |
| Entera Bio Ltd. | 1.37 Million USD | -19265.192% |
| GH Research PLC | 6.7 Million USD | -3885.166% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -3827.147% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -1318.496% |
| Xencor, Inc. | 283.55 Million USD | 5.823% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -8844.242% |
| Replimune Group, Inc. | 113.21 Million USD | -135.877% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -7007.722% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -157.941% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -66015.551% |
| Portage Biotech Inc. | 4.45 Million USD | -5901.034% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -17652.873% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -1058.551% |
| OncoCyte Corporation | 49.29 Million USD | -441.697% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -6355.368% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -33386.064% |
| Purple Biotech Ltd. | 10 Million USD | -2569.125% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -4515.382% |
| scPharmaceuticals Inc. | 57.26 Million USD | -366.366% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -2055.679% |
| HilleVax, Inc. | 78.9 Million USD | -238.423% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -5188.04% |
| Tharimmune, Inc. | 1.81 Million USD | -14612.905% |
| Genprex, Inc. | 3.25 Million USD | -8106.175% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -884.719% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -5000.191% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -129533.981% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -74379.846% |
| OKYO Pharma Limited | 7.42 Million USD | -3498.592% |
| Savara Inc. | 37.19 Million USD | -618.02% |
| Curis, Inc. | 57.61 Million USD | -363.525% |
| Daré Bioscience, Inc. | 26.32 Million USD | -914.233% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -581.243% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -18393.49% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -1182.703% |
| BeiGene, Ltd. | 2.23 Billion USD | 88.045% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -1154.338% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | -1.772% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -1155.269% |
| Erasca, Inc. | 78.61 Million USD | -239.706% |
| bluebird bio, Inc. | 424.62 Million USD | 37.11% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -40654.702% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 85.871% |
| DBV Technologies S.A. | 42.8 Million USD | -523.939% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -40654.702% |
| Moderna, Inc. | 4.57 Billion USD | 94.159% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -3717.67% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -16025.966% |
| Molecular Templates, Inc. | 31.17 Million USD | -756.713% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -1464.417% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 54.592% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -114.486% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -873.306% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -632.516% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -379.996% |
| MacroGenics, Inc. | 154.2 Million USD | -73.174% |
| RenovoRx, Inc. | 4.46 Million USD | -5879.534% |
| Adicet Bio, Inc. | 37.12 Million USD | -619.413% |
| Prime Medicine, Inc. | 60.78 Million USD | -339.365% |
| Aditxt, Inc. | 28.53 Million USD | -835.967% |
| Adagene Inc. | 45.16 Million USD | -491.211% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -147683.355% |
| Quantum-Si incorporated | 26.63 Million USD | -902.764% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 61.717% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -8677.369% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -132.293% |
| SciSparc Ltd. | 1.59 Million USD | -16642.696% |
| Vericel Corporation | 127.7 Million USD | -109.112% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -4698.762% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -212.854% |
| Generation Bio Co. | 171.63 Million USD | -55.594% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -2212.087% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -538.393% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | -5.678% |
| Invivyd, Inc. | 51.71 Million USD | -416.4% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -190.34% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -4005.084% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -253.722% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -26055.338% |
| 2seventy bio, Inc. | 310.12 Million USD | 13.891% |
| ADMA Biologics, Inc. | 193.97 Million USD | -37.67% |
| Clene Inc. | 38.95 Million USD | -585.595% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -639.067% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | -3.919% |
| GeoVax Labs, Inc. | 3.51 Million USD | -7486.791% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -40.356% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -2092.557% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -34.653% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -2089.835% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -455.062% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -405.377% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 27.797% |
| Evaxion Biotech A/S | 17.61 Million USD | -1415.801% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -65.94% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -74.328% |
| Trevena, Inc. | 48.26 Million USD | -453.326% |
| Surrozen, Inc. | 8.14 Million USD | -3178.649% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -1136.61% |
| Cingulate Inc. | 10.36 Million USD | -2477.449% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -9610.764% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -616.095% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -7345.825% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -1930.768% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 15.812% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -974.675% |
| Clearmind Medicine Inc. | 3.61 Million USD | -7297.38% |
| Kronos Bio, Inc. | 54.2 Million USD | -392.696% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -467.664% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -1073.327% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1230.507% |
| Statera Biopharma, Inc. | 22.67 Million USD | -1077.636% |
| ImmunityBio, Inc. | 1.09 Billion USD | 75.509% |
| Korro Bio, Inc. | 51.75 Million USD | -416.011% |
| Kineta, Inc. | 7.22 Million USD | -3597.674% |
| BioVie Inc. | 9.7 Million USD | -2652.447% |
| Codexis, Inc. | 49.94 Million USD | -434.669% |
| Celularity Inc. | 102.92 Million USD | -159.447% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -177.459% |
| Celcuity Inc. | 51.45 Million USD | -419.039% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -77261.136% |
| Cibus, Inc. | 206.11 Million USD | -29.56% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -528.713% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -913.881% |
| IN8bio, Inc. | 8.77 Million USD | -2944.3% |
| Kodiak Sciences Inc. | 213.59 Million USD | -25.027% |
| Annexon, Inc. | 47.11 Million USD | -466.76% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -198.239% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -177.099% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -1850.807% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 89.742% |
| Eyenovia, Inc. | 19.78 Million USD | -1250.062% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -50.8% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -3376.709% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -1008.121% |
| Arcellx, Inc. | 339.75 Million USD | 21.4% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -2144.461% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | -8.759% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -2692.492% |
| Moolec Science SA | 13.94 Million USD | -1814.946% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -518.85% |
| Geron Corporation | 146.12 Million USD | -82.749% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -428.469% |
| Royalty Pharma plc | 6.29 Billion USD | 95.76% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -571.375% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -90606.711% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -10754.284% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -41.178% |
| Humacyte, Inc. | 114.67 Million USD | -132.868% |
| Structure Therapeutics Inc. | 29.05 Million USD | -819.232% |
| 89bio, Inc. | 59.96 Million USD | -345.351% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -909.13% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -22228.261% |
| Genelux Corporation | 8.42 Million USD | -3071.568% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -3795.07% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -95.898% |
| Notable Labs, Ltd. | 4.42 Million USD | -5932.211% |
| Liquidia Corporation | 73.13 Million USD | -265.126% |
| Mustang Bio, Inc. | 17.61 Million USD | -1415.671% |
| Immunovant, Inc. | 48.95 Million USD | -445.493% |
| Quantum-Si incorporated | 26.63 Million USD | -902.764% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -595.74% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -8506.059% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -261.552% |
| Acasti Pharma Inc. | 11.55 Million USD | -2210.686% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -1081.215% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -9723.625% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -624.153% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -19494.788% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -4280.676% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -975.281% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -1051.855% |
| PepGen Inc. | 34.63 Million USD | -671.118% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -2098.995% |
| United Therapeutics Corporation | 1.18 Billion USD | 77.411% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -3723.683% |
| Solid Biosciences Inc. | 38.45 Million USD | -594.383% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -3020.72% |
| Immuneering Corporation | 12 Million USD | -2123.835% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -84984.975% |
| Silo Pharma, Inc. | 1.56 Million USD | -16917.212% |
| Belite Bio, Inc | 4.21 Million USD | -6241.629% |
| XOMA Corporation | 145.58 Million USD | -83.436% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -10898.6% |
| Bionomics Limited | 10.15 Million USD | -2528.736% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -1142.595% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -1065.478% |
| uniQure N.V. | 624.01 Million USD | 57.205% |
| Cassava Sciences, Inc. | 14.19 Million USD | -1781.268% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -147683.355% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -56.916% |
| Forte Biosciences, Inc. | 3.66 Million USD | -7184.397% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -102380.208% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -3857.996% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -3376.709% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1436.248% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -2426.93% |
| Altimmune, Inc. | 16.54 Million USD | -1514.449% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 56.768% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -1065.478% |
| Compugen Ltd. | 55.77 Million USD | -378.792% |
| Peak Bio, Inc. | 20.75 Million USD | -1186.76% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -141.752% |
| Benitec Biopharma Inc. | 4.96 Million USD | -5281.822% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -69.185% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -255.237% |
| Zura Bio Limited | 21.29 Million USD | -1154.208% |
| PolyPid Ltd. | 17.46 Million USD | -1428.773% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -137.588% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -255.237% |
| Instil Bio, Inc. | 99.8 Million USD | -167.578% |
| argenx SE | 444.95 Million USD | 39.983% |
| Immunome, Inc. | 28.65 Million USD | -831.838% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -3103.143% |
| Verona Pharma plc | 58.84 Million USD | -353.843% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -1745.132% |
| Shattuck Labs, Inc. | 14.85 Million USD | -1697.2% |
| CervoMed Inc. | 2.59 Million USD | -10187.829% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -5378.991% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -1996.781% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -2434.846% |
| Moolec Science SA | 13.94 Million USD | -1814.946% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -11295.159% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -380.339% |
| AnaptysBio, Inc. | 364.28 Million USD | 26.693% |
| Design Therapeutics, Inc. | 11.95 Million USD | -2133.573% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -2005.377% |
| NeurAxis, Inc. | 1.91 Million USD | -13861.445% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -586.0% |
| Lumos Pharma, Inc. | 13.33 Million USD | -1902.895% |
| Achilles Therapeutics plc | 19.08 Million USD | -1299.099% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -1745.132% |
| 180 Life Sciences Corp. | 5.38 Million USD | -4857.038% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -1032.127% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -1073.327% |
| Nutriband Inc. | 1.07 Million USD | -24651.256% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -772.756% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -1740.3% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 33.45% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -722.363% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -1946.471% |
| Palisade Bio, Inc. | 2.73 Million USD | -9649.763% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -4983.686% |
| Beam Therapeutics Inc. | 478.38 Million USD | 44.178% |
| Neurogene Inc. | 36.54 Million USD | -630.652% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 32.895% |
| AEON Biopharma, Inc. | 159.88 Million USD | -67.02% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -460.432% |
| Sesen Bio, Inc. | 30.98 Million USD | -761.884% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -928.643% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -3412.739% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -36.43% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -39.045% |
| Athira Pharma, Inc. | 30.05 Million USD | -788.465% |
| Vaccinex, Inc. | 5.94 Million USD | -4394.211% |
| HCW Biologics Inc. | 15.05 Million USD | -1674.163% |
| XOMA Corporation | 145.58 Million USD | -83.436% |
| Arvinas, Inc. | 644.6 Million USD | 58.572% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1405.916% |
| Merus N.V. | 102.15 Million USD | -161.423% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -82.471% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -180.746% |
| Rezolute, Inc. | 11.73 Million USD | -2175.831% |
| Clene Inc. | 38.95 Million USD | -585.595% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -9278.657% |
| BeyondSpring Inc. | 48.26 Million USD | -453.245% |
| Synlogic, Inc. | 32.89 Million USD | -711.813% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -1727.455% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -16243.084% |
| Peak Bio, Inc. | 20.75 Million USD | -1186.76% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -320.817% |
| Krystal Biotech, Inc. | 39.71 Million USD | -572.423% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 29.099% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -168.202% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -61612.492% |
| MannKind Corporation | 721.36 Million USD | 62.981% |
| Ikena Oncology, Inc. | 22.33 Million USD | -1095.639% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -12701.822% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -160.304% |
| Gossamer Bio, Inc. | 249.14 Million USD | -7.184% |
| CohBar, Inc. | 1.03 Million USD | -25735.544% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -2398.325% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1301.963% |
| Legend Biotech Corporation | 589.93 Million USD | 54.733% |
| Mural Oncology plc | 37.92 Million USD | -604.087% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -101.337% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -11534.308% |
| Disc Medicine, Inc. | 22.87 Million USD | -1067.414% |
| Champions Oncology, Inc. | 28.03 Million USD | -852.545% |
| REGENXBIO Inc. | 262.22 Million USD | -1.837% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -7849.331% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -2030.573% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -1888.188% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -1159.354% |
| Vaxart, Inc. | 34.02 Million USD | -684.852% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -1209.738% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -835.957% |
| Cellectis S.A. | 249.57 Million USD | -7.0% |
| Longeveron Inc. | 5.33 Million USD | -4903.672% |
| Repare Therapeutics Inc. | 41.81 Million USD | -538.576% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 88.897% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -342.364% |
| Revolution Medicines, Inc. | 262.39 Million USD | -1.772% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -12574.229% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -2995.827% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -2162.91% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -1801.631% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -12314.97% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 94.814% |
| Denali Therapeutics Inc. | 122.96 Million USD | -117.176% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -4698.762% |
| Veru Inc. | 32.81 Million USD | -713.849% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -3787.698% |
| Cingulate Inc. | 10.36 Million USD | -2477.449% |
| Passage Bio, Inc. | 39.26 Million USD | -580.164% |
| Context Therapeutics Inc. | 4.19 Million USD | -6270.805% |
| Exicure, Inc. | 8.54 Million USD | -3023.71% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -804.995% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -2446.691% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -1111.587% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -63.846% |
| Nuvalent, Inc. | 31.82 Million USD | -739.16% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -4097.763% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -323.735% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -1383.589% |
| OmniAb, Inc. | 87.4 Million USD | -205.545% |
| Anew Medical, Inc. | 8.24 Million USD | -3140.142% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -597.447% |
| Lipocine Inc. | 2.63 Million USD | -10047.555% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -916.466% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -564.095% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -902.357% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -209.964% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -4844.381% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -222.726% |
| Ocugen, Inc. | 23.98 Million USD | -1013.48% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -475.443% |
| Q32 Bio Inc. | 233.12 Million USD | -14.549% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -2845.577% |
| Alumis Inc. Common Stock | 53.5 Million USD | -399.133% |
| Equillium, Inc. | 27.95 Million USD | -855.203% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -29.263% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -4646.08% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -4254.27% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -69.741% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -284.61% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -2577.367% |
| Dominari Holdings Inc. | 4.63 Million USD | -5661.51% |
| Edesa Biotech, Inc. | 1.84 Million USD | -14400.469% |
| vTv Therapeutics Inc. | 29.56 Million USD | -803.189% |
| Bio-Techne Corporation | 744.34 Million USD | 64.123% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -111.775% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 22.473% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -558.154% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -822.216% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -189.136% |
| Nkarta, Inc. | 105.6 Million USD | -152.884% |
| BioCardia, Inc. | 4.59 Million USD | -5717.996% |
| Iterum Therapeutics plc | 32.66 Million USD | -717.605% |